CHINARES PHARMA's subsidiary BOYA BIOLOGY's blood plasma collection station has been issued a business license by the Market Supervision Administration of Dalat Qi

CHINARES PHARMA (03320.HK) announced that its subsidiary BOYA BIOLOGY's single plasma collection station "Dalateqi BOYA Single Plasma Collection Co., Ltd." has obtained a "Business License" issued by the Dalateqi Market Supervision Administration, granting permission for the collection and supply of raw plasma.

The Dalateqi plasma station will be constructed in accordance with relevant laws, regulations, and standards. After completion, it will submit a practice application in accordance with the "Management Measures for Single Plasma Collection Stations" and other relevant requirements, and will commence plasma collection work after passing inspection.

The group stated that the issuance of the business license for the Dalateqi plasma station is a key step in solidifying the strategic foundation of raw plasma for BOYA BIOLOGY, which will have a positive impact on the overall operations of the group. In the future, CHINARES PHARMA will steadily expand plasma station resources and continuously improve the quality of plasma station services